ADMA Biologics (ADMA)
NASDAQ:ADMA
Earnings Data
Report Date
May 13, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.2Last Year’s EPS
0.14Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial narrative: substantial revenue growth (20% YoY), pronounced margin expansion (gross margin up to 57.4% FY, 63.8% exit Q4), and significant product-level momentum with Ascentive (+51% YoY to $363M). Management highlighted structural improvements from yield-enhanced production, expanded plasma supply visibility, and ambitious multi-year guidance. Near-term challenges were acknowledged — elevated working capital/AR due to rapid growth, the cash position excluding divestiture proceeds, and timing risks around distribution ramps and closing the divestiture — but management provided clear remediation paths (working capital focus, new CFO hire, McKesson ramp). Overall, the highlights numerically and qualitatively outweigh the lowlights.Company Guidance
Strong Full-Year Financial Performance
Total revenue of $510,200,000 for FY2025, representing 20% year-over-year growth; adjusted EBITDA of $231,000,000, up 40% YoY; adjusted net income of $160,800,000, up 35% YoY — demonstrating expanding profitability and operating leverage.
Ascentive Product Surge
Ascentive achieved $363,000,000 in net revenue in 2025, a 51% year-over-year increase; company reported a roughly 70/30 split between Ascentive and Bivigam in 2025 and described record utilization and strong prescriber adoption.
Margin Expansion and Yield-Enhanced Production
FY2025 gross margin expanded to 57.4% from 51.5% in 2024 (≈6.0 percentage-point improvement); corporate Q4 2025 gross margin exited at 63.8% (approximately 10% YoY improvement in exit margin). Management attributed margin gains to full integration of yield-enhanced production into commercial operations.
Robust Quarter-End Results
Q4 2025 total revenue of $139,200,000 (up 18% YoY); Q4 adjusted EBITDA of $73,600,000, up 52% YoY; Q4 adjusted net income of $52,600,000, up 57% YoY — indicating accelerating profitability into year-end.
Ambitious and Upward Guidance
2026 guidance: revenue > $635,000,000, adjusted net income > $255,000,000, adjusted EBITDA > $360,000,000. 2027 guidance: revenue > $775,000,000, adjusted EBITDA > $455,000,000. 2029 target: revenue > $1,100,000,000 and adjusted EBITDA > $700,000,000.
Improved Plasma Supply Visibility and Network Repositioning
Strategic repositioning includes monetizing 3 plasma centers while retaining 7 and executing long-term supply agreements; company now has access to over 280 plasma collection centers and improved supply visibility into the late 2030s.
Real-World Evidence and Clinical Validation
Independent peer-reviewed study (Tan et al.) presented/published in 2025 showed statistically significant reductions in infections and hospitalizations for patients who failed prior IVIG and transitioned to Ascentive; 71% of those patients showed clinical improvement, with additional publications expected in 2026.
Leadership and Financial Execution Focus
Planned CFO transition from retiring Brad Tade to incoming Terry Kohler (with expertise in working capital optimization and cash conversion) to support disciplined execution; company reported $88,000,000 in cash at year-end (excluding divestiture proceeds) and expects improving cash generation in 2026.
ADMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $15.68 | $15.18 | -3.19% |
Nov 05, 2025 | $15.37 | $14.03 | -8.72% |
Aug 06, 2025 | $18.54 | $16.75 | -9.65% |
May 07, 2025 | $23.61 | $21.20 | -10.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ADMA Biologics (ADMA) report earnings?
ADMA Biologics (ADMA) is schdueled to report earning on May 13, 2026, TBA (Confirmed).
What is ADMA Biologics (ADMA) earnings time?
ADMA Biologics (ADMA) earnings time is at May 13, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADMA EPS forecast?
ADMA EPS forecast for the fiscal quarter 2026 (Q1) is 0.2.